Just reading your post. I, also, had triple therapy with Taxotere/Darolutamide/Lupron for oligo metastatic disease last quarter of 2022. PSA rapidly became undetectable and has remained so with last PSA 7/22/24 < 0.014.

My Johns Hopkins MO is highly experienced. He has written/co-authored over 350 peer reviewed articles on prostate cancer and is very involved in research and trials. He discontinued my Darolutamide after 3 months and I only had 4 chemo cycles as he said there is no scientific proof that additional chemo is more effective. My Lupron/ADT was discontinued after one year.

I am a retired physician and did a lot of research before deciding on Hopkins to get my treatment. I am curious if you have any actual clinical trial data that more chemo sessions are beneficial to overall survival?

I believe that my MO believes that once the PSA becomes undetectable (and remains there for some period of time) that taking the patient off all medication is beneficial. Of course, eliminating any SEs is helpful. But I wonder if not exposing any residual micro mets to the continued use of Darolutamide (or other agent) keeps the resistant, more aggressive clones from developing.

Of course, at this time nobody really knows. I have to put my faith in an expert and follow their advice. Do you have any additional thoughts?

Good luck and prayers with you.